Autopsy report · NCT02436135
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Cause of deathNo reason given
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 5 months before it stopped.
- 10 participants enrolled.
- Results were posted on the registry 2 years 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Myelofibrosis
- Interventions
- Idelalisib; Ruxolitinib
- Participants
- 10
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.